Parexel launches advisory service dedicated to Chinese market

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Tuangtong)
(Image: Getty/Tuangtong)

Related tags China Parexel Clinical trials

Parexel is launching a new advisory service to help clients navigate the market opportunities in China.

The biopharmaceutical services provider has launched a new China Advisory Service. The offering includes overall strategy, agency engagement and agreements, early development, clinical operations, and regulatory, market access, and commercial strategies support.

Several regulatory changes in China over the past few years​ are expected to accelerate drug development timelines.

Earlier this year, the Chinese Premier Li Keqiang announced​ several developments during an executive meeting of the State Council of the People's Republic of China last month. Of the highlighted developments, plans include those “to enhance quality supervision,” establish “intensified on-site inspection of foreign drugs’ production,” and double down on counterfeit drugs, according to the release from the State Council.

Read more: Chinese gov't outlines changes to import tariff, clinical trial applications, IP protection

China also now accepts clinical trial data from other countries following a new guideline released last yea​r that aims to reform the management of clinical trials.

Over the next 10 years, the Chinese market is expected to see “high growth,”​ as health care currently accounts for just 7% of the overall government expense – leaving room to expand, Mingping Zhang, vice president, technical, Parexel Consulting, told us in June.

The Chinese pharmaceutical market recently outpaced Japan to become the second largest market globally.

Parexel has been operating in China for more than 19 years and employs more than 1,400 employees in seven offices across the country.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more